-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OeQBnH75jybPF23Kg4o1y/D9+MbX2QNUQk8/b4VylWfpFWL1KKr4tDnhKpQbxXil 7aWG5GlCaBQ7sKa1CQ4XaA== 0001127602-10-007291.txt : 20100303 0001127602-10-007291.hdr.sgml : 20100303 20100303190541 ACCESSION NUMBER: 0001127602-10-007291 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100301 FILED AS OF DATE: 20100303 DATE AS OF CHANGE: 20100303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LUNDEMOSE ANKER MD, PH.D, DSC CENTRAL INDEX KEY: 0001314821 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 10655005 MAIL ADDRESS: STREET 1: C/O OSI PHARMACEUTICALS, INC. STREET 2: 58 SOUTH SERVICE ROAD, SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2010-03-01 0000729922 OSI PHARMACEUTICALS INC OSIP 0001314821 LUNDEMOSE ANKER MD, PH.D, DSC C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD NEW YORK NY 11747 1 EVP, Corp. Dev & Strategic Pln Common Stock 2010-03-01 4 M 0 15200 35.10 A 46823 D Common Stock 2010-03-01 4 M 0 13000 29.77 A 59823 D Common Stock 2010-03-01 4 S 0 29200 55.20 D 30623 D Stock Option (Right to Buy) 35.10 2010-03-01 4 M 0 15200 0 D 2005-02-11 2014-02-10 Common Stock 15200 0 D Stock Option (Right to Buy) 29.77 2010-03-01 4 M 0 13000 0 D 2007-06-13 2013-06-12 Common Stock 13000 5000 D Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 3, 2009. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $55.15 to $55.32 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. One third of the stock options became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months. 25% of the option became exercisable one year after the date of grant and the remainder vests ratably on an annual basis over the succeeding 3 years. Includes only options with the same termination date. /s/ Pierre Legault, attorney-in-fact for Dr. Lundemose 2010-03-03 -----END PRIVACY-ENHANCED MESSAGE-----